E P Winer

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
  2. pmc New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:204-10. 2004
  3. pmc Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
    Jennifer A Ligibel
    Harvard Medical School, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Breast Cancer Res 7:255-7. 2005
  4. ncbi request reprint American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
  5. ncbi request reprint Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:2061-8. 2004
  6. ncbi request reprint New combinations with Herceptin in metastatic breast cancer
    E P Winer
    Dana Farber Cancer Institute, Boston, Mass 02115, USA
    Oncology 61:50-7. 2001
  7. ncbi request reprint The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 106:2576-82. 2006
  8. doi request reprint A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N U Lin
    Department of Medical Oncology, Division of Women s Cancers, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 139:403-10. 2013
  9. ncbi request reprint New cytotoxic agents and schedules for advanced breast cancer
    H J Burstein
    Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 28:344-58. 2001
  10. ncbi request reprint Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:5178-87. 2005

Research Grants

  1. CANCER AND LEUKEMIA GROUP B
    Eric Winer; Fiscal Year: 2006

Detail Information

Publications106 found, 100 shown here

  1. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  2. pmc New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:204-10. 2004
    ....
  3. pmc Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
    Jennifer A Ligibel
    Harvard Medical School, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Breast Cancer Res 7:255-7. 2005
    ..Ongoing trials will compare these approaches and guide the use of these agents in the years to come...
  4. ncbi request reprint American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  5. ncbi request reprint Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:2061-8. 2004
    ..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
  6. ncbi request reprint New combinations with Herceptin in metastatic breast cancer
    E P Winer
    Dana Farber Cancer Institute, Boston, Mass 02115, USA
    Oncology 61:50-7. 2001
    ..These and other studies will identify the regimens that produce the best outcomes with the fewest possible side effects in women with HER2-positive breast cancer...
  7. ncbi request reprint The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 106:2576-82. 2006
    ..However, the optimal sequencing of AIs and tamoxifen as adjuvant therapy is not known and may differ for biologic subsets of cancers...
  8. doi request reprint A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N U Lin
    Department of Medical Oncology, Division of Women s Cancers, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 139:403-10. 2013
    ..Additionally, unacceptable toxicity was observed, at rates greater than previously reported with vinorelbine/trastuzumab or vinorelbine/bevacizumab doublet combinations...
  9. ncbi request reprint New cytotoxic agents and schedules for advanced breast cancer
    H J Burstein
    Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 28:344-58. 2001
    ..The growing availability of such biological therapies given in combination with chemotherapy may mean better survival in the future for women with advanced breast cancer...
  10. ncbi request reprint Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:5178-87. 2005
    ..Options include the antiestrogen tamoxifen, estrogen deprivation with aromatase inhibitors, and sequential therapy with tamoxifen and then an aromatase inhibitor...
  11. ncbi request reprint Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer
    Eric P Winer
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, USA
    N Engl J Med 357:1640-8. 2007
  12. doi request reprint Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
    E L Mayer
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA
    Breast Cancer Res Treat 117:615-23. 2009
    ..This phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC)...
  13. pmc Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
    K J Ruddy
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Ann Oncol 23:3075-81. 2012
    ..We sought to measure persistence with CMF, adherence to oral cyclophosphamide, and the association of these with toxic effects...
  14. ncbi request reprint Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
    H J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann Oncol 16:1772-7. 2005
    ..The aim of this study was to characterize the prevalence and predictors of central nervous system (CNS) metastasis among women with HER2-overexpressing metastatic breast cancer receiving trastuzumab-based therapy...
  15. ncbi request reprint Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    H J Burstein
    Division of Adult Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:2722-30. 2001
    ..CONCLUSION: Trastuzumab in combination with vinorelbine is highly active in women with HER2-overexpressing advanced breast cancer and is well tolerated...
  16. doi request reprint Advances in adjuvant endocrine therapy for postmenopausal women
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Mayer 232, Boston, MA 02115, USA
    J Clin Oncol 26:798-805. 2008
    ..We outline controversies in choosing the optimal endocrine approach, and we discuss selected ongoing studies. Finally, we highlight future research directions, such as the need to understand host and tumor heterogeneity...
  17. doi request reprint American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
    ..To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer...
  18. ncbi request reprint Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 112:673-8. 2008
    ..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer...
  19. ncbi request reprint Trastuzumab/chemotherapy combinations in metastatic breast cancer
    Jennifer A Ligibel
    Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 29:38-43. 2002
    ....
  20. doi request reprint A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases
    Susana M Campos
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 9:39-44. 2009
    ..Recent aromatase inhibitor studies have reported activity in such patients; therefore, this study formally evaluated anastrozole and exemestane in postmenopausal patients in this setting...
  21. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  22. ncbi request reprint Long-term complications of adjuvant chemotherapy for early stage breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Breast Dis 21:55-64. 2004
    ..Interventions to ameliorate long-term complications are also addressed...
  23. ncbi request reprint Local therapy and survival in breast cancer
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 356:2399-405. 2007
  24. pmc A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    S M Tolaney
    Departments of Medical Oncology, Dana FarberCancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA 02215, USA
    Ann Oncol 24:1841-7. 2013
    ..A multicenter NCI-sponsored phase II study was conducted to analyze the safety and efficacy of the combination of ixabepilone with trastuzumab in patients with metastatic HER2-positive breast cancer...
  25. pmc Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
    E M Olson
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Ann Oncol 23:93-7. 2012
    ..It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1)...
  26. doi request reprint Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    M Golshan
    Department of Surgery, Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg Oncol 18:733-7. 2011
    ..There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC)...
  27. ncbi request reprint Clinical differences among the aromatase inhibitors
    Jennifer A Ligibel
    Harvard Medical School, Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:473S-9S. 2003
    ..This article explores the efficacy and tolerability of the aromatase inhibitors in both the metastatic and the adjuvant settings...
  28. pmc Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
    ..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
  29. ncbi request reprint Surveillance testing among survivors of early-stage breast cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:1074-81. 2007
    ..We described follow-up care for breast cancer survivors, examined how surveillance testing varies by the types of physicians seen, and assessed changes in testing rates over time...
  30. doi request reprint A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Breast Cancer Res Treat 140:331-9. 2013
    ..PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. ..
  31. pmc Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
    I Vaz-Luis
    Department of Medical Oncology, Breast Oncology Center, Dana Farber Cancer Institute, Boston, MA 02215 USA
    Ann Oncol 24:283-91. 2013
    ..Accumulating data indicate that HER2-positive disease is itself a heterogeneous entity...
  32. ncbi request reprint Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
    P W Kantoff
    Lank Center for Genitourinary Oncology and Breast Oncology Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Clin Oncol 17:2506-13. 1999
    ..The purpose of this study was to demonstrate an advantage of mitoxantrone and hydrocortisone (M+H) over hydrocortisone alone with respect to survival duration...
  33. ncbi request reprint Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:369-75. 2007
    ..Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial...
  34. ncbi request reprint Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study
    Harold J Burstein
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer 110:965-72. 2007
    ..The trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare these regimens...
  35. doi request reprint The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care
    Rachel A Freedman
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 117:180-9. 2011
    ..The authors examined care for a national cohort of breast cancer patients to assess whether insurance and SES were associated with racial/ethnic differences in care...
  36. ncbi request reprint Follow-up care of patients with breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA
    Breast 16:S45-50. 2007
    ..With the growing number of breast cancer survivors, further studies should be undertaken to study the cost-effectiveness of surveillance strategies...
  37. ncbi request reprint Sarcoidosis mimicking metastatic breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Breast Cancer 7:804-10. 2007
    ..We describe 3 patients who presented with locally advanced breast cancer and who were found to have pulmonary findings for metastatic disease that were proven upon biopsy to be consistent with sarcoidosis...
  38. doi request reprint Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer
    Jennifer A Ligibel
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    J Womens Health (Larchmt) 19:1553-9. 2010
    ..Studies have suggested that decreases in physical activity during treatment may contribute to weight gain in breast cancer patients...
  39. ncbi request reprint Web-based survey of fertility issues in young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:4174-83. 2004
    ..Young women with breast cancer often seek advice about whether treatment will affect their fertility. We sought to gain a better understanding of women's attitudes about fertility and how these concerns affect decision making...
  40. pmc Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:4109-15. 2008
    ..However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied...
  41. doi request reprint Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ
    Jennifer A Ligibel
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann Surg Oncol 16:106-12. 2009
    ..Women who underwent mastectomy, as well as women who were more anxious, were more likely to decrease their level of physical activity. Women with DCIS might benefit from targeted interventions to increase physical activity...
  42. ncbi request reprint Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
    ....
  43. doi request reprint Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors
    Jennifer A Ligibel
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Causes Control 20:1523-8. 2009
    ..This study examines the impact of exercise upon levels of adiponectin, high molecular weight adiponectin (HMWA), and leptin in breast cancer survivors...
  44. doi request reprint Fertility and menopausal outcomes in young breast cancer survivors
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Breast Cancer 8:65-9. 2008
    ..We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival Coalition, an international advocacy group for young women with breast cancer...
  45. pmc Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 100:642-8. 2008
    ....
  46. ncbi request reprint VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:7871-7. 2008
    ....
  47. doi request reprint Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors
    Jennifer A Ligibel
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Channing Laboratory, Boston, MA, USA
    J Clin Oncol 26:907-12. 2008
    ..We sought to analyze whether exercise lowered insulin concentrations in breast cancer survivors...
  48. ncbi request reprint Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer
    Rachel A Freedman
    Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast 19:69-75. 2010
    ....
  49. pmc Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:2638-45. 2008
    ..The purpose of the current study was to characterize the outcomes of patients with metastatic triple-negative breast cancers, including the risk and clinical consequences of central nervous system (CNS) recurrence...
  50. ncbi request reprint Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8340-7. 2005
    ..The role of long-acting hematopoietic growth factors in facilitating every-2-week chemotherapy and minimizing hematologic toxicity has not been established...
  51. ncbi request reprint Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
    ..We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer...
  52. ncbi request reprint Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:629-32. 2004
    ..Future studies should consider sharing trial results with patients and evaluating the process and its effect on both patients and clinicians...
  53. ncbi request reprint Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
    ..We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy...
  54. ncbi request reprint Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8453-60. 2005
    ..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients...
  55. ncbi request reprint Offering participants results of a clinical trial: sharing results of a negative study
    Ann H Partridge
    Department of Medical and Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 365:963-4. 2005
    ..006). Most participants reported positive feelings about being offered results and about clinical trials in general. These preliminary findings from sharing clinical trial results are encouraging...
  56. ncbi request reprint Hormonal therapy in postmenopausal women with breast cancer
    Susana M Campos
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncology 64:289-99. 2003
    ..In addition to their role in metastatic breast, trials investigating the potential of aromatase inhibitors in the early breast cancer, both in the adjuvant and neoadjuvant setting are underway...
  57. ncbi request reprint Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 12:997s-1000s. 2006
  58. ncbi request reprint Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 64:496-504. 2006
    ..To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC)...
  59. ncbi request reprint Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:161-4. 2007
    ..Rebeccamycin analog is reasonably well tolerated on two different treatment schedules for advanced breast cancer, with modest clinical activity in this heavily pretreated population...
  60. ncbi request reprint Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:2889-95. 2003
    ..We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined with vinorelbine, and to assess cardiac surveillance algorithms and tumor markers as prognostic tools...
  61. ncbi request reprint Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 79:391-7. 2003
    ..To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer...
  62. doi request reprint Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship
    K J Ruddy
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Ann Oncol 24:1434-43. 2013
    ..The causes, optimal treatments, and medical/psychosocial sequelae of breast cancer in men are poorly understood...
  63. ncbi request reprint Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
    L C Collins
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, USA
    Breast Cancer Res Treat 131:1061-6. 2012
    ..These findings may have implications with regard to the etiology and prognosis of breast cancer in young women...
  64. ncbi request reprint Brain metastases: the HER2 paradigm
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1648-55. 2007
    ..Finally, new developments in systemic approaches to the treatment of CNS disease, including cytotoxic chemotherapy and targeted therapy, are explored...
  65. ncbi request reprint Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  66. ncbi request reprint Cancer and leukemia group B breast committee: decades of progress and plans for the future
    Clifford A Hudis
    Memorial Sloan Kettering Cancer Center, New York, New York and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 12:3576s-80s. 2006
    ..Current and future projects are aimed at exploiting and increasing our growing knowledge of the molecular biology of breast cancer by developing targeted therapies...
  67. doi request reprint Heterogeneity of breast cancer and implications of adjuvant chemotherapy
    A Rab Razzak
    Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer 15:31-4. 2008
    ..In the future, breast cancer treatment will be more targeted to the tumor and tailored to the individual with the use of genomic and clinical data...
  68. ncbi request reprint Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, 180 Longwood Avenue, Boston, MA 02115, USA
    Med Care 47:765-73. 2009
    ..Prior research has documented racial disparities in patterns of care and outcomes for women with breast cancer...
  69. ncbi request reprint Menopausal-type symptoms in young breast cancer survivors
    M G Leining
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
    Ann Oncol 17:1777-82. 2006
    ..There has been little previous information available about menopausal-type symptoms in very young breast cancer survivors...
  70. doi request reprint Attitudes of patients with metastatic breast cancer toward research biopsies
    D S Seah
    Deparment of Medical Oncology, Dana Farber Cancer Institute, Boston MA02215, USA
    Ann Oncol 24:1853-9. 2013
    ..Research studies involving human tissue are increasingly common. However, patients' attitudes toward research biopsies are not well characterized, particularly when the biopsies are carried out outside the context of therapeutic trials...
  71. doi request reprint The impact of sharing results of a randomized breast cancer clinical trial with study participants
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 115:123-9. 2009
    ..We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results...
  72. ncbi request reprint Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer
    Nancy L Keating
    Department of Medicine, Brigham and Women s Hospital, and Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:4532-9. 2003
    ..We assessed whether consultation with a medical oncologist before surgery was associated with use of definitive surgery, axillary node dissection, and type of surgery...
  73. ncbi request reprint CNS metastases in breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 22:3608-17. 2004
    ..Studies specifically targeted toward this group of patients are needed...
  74. ncbi request reprint Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses
    Leslie G Bluman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Psychooncology 12:410-27. 2003
    ..Overall, spouses were satisfied with their role in the decision-making process. Future interventions to improve the decision-making process regarding genetic testing for breast cancer susceptibility should be undertaken...
  75. doi request reprint Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
    Andrea C Bafford
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Breast Cancer Res Treat 115:7-12. 2009
    ..Retrospective analyses suggest patients with stage IV breast cancer who undergo breast surgery have improved survival. We sought to determine whether surgery and other clinical and staging factors affected overall survival...
  76. ncbi request reprint Adherence to therapy with oral antineoplastic agents
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 94:652-61. 2002
    ..Assessment of adherence among individuals with cancer and implementation of interventions in situations of poor adherence should improve clinical outcomes...
  77. doi request reprint Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1452-9. 2009
    ..The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine...
  78. pmc Care in the months before death and hospice enrollment among older women with advanced breast cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Gen Intern Med 23:11-8. 2008
    ..Variations in hospice use are not well understood...
  79. ncbi request reprint Factors related to underuse of surveillance mammography among breast cancer survivors
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 24:85-94. 2006
    ..We identified factors associated with underuse of surveillance mammography and examined whether variation was explained by differences in follow-up care...
  80. ncbi request reprint Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  81. ncbi request reprint Quality of non-breast cancer health maintenance among elderly breast cancer survivors
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, Boston 02115, USA
    J Clin Oncol 21:1447-51. 2003
    ..To assess the quality of preventive health care, the role of health care participation, and the patient and provider characteristics associated with high-quality care for breast cancer survivors...
  82. ncbi request reprint Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ
    L G Bluman
    Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Womens Health Gend Based Med 10:589-98. 2001
    ..In view of the frequency of the DCIS diagnosis, future investigation should be conducted to build on these findings...
  83. ncbi request reprint American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting
    Eric P Winer
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 21:2597-9. 2003
  84. ncbi request reprint American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002
    Eric P Winer
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3317-27. 2002
    ..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane...
  85. ncbi request reprint American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
    Rowan T Chlebowski
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3328-43. 2002
    ..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide...
  86. ncbi request reprint Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  87. ncbi request reprint HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
    J Clin Oncol 22:854-63. 2004
    ..Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies...
  88. ncbi request reprint Dose density in breast cancer: a simple message?
    Nancy U Lin
    J Natl Cancer Inst 97:1712-4. 2005
  89. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  90. ncbi request reprint Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer
    David Thompson
    i3 Innovus, Medford, MA 02155, USA
    Value Health 10:367-76. 2007
    ..We sought to evaluate the cost-effectiveness of this management strategy...
  91. ncbi request reprint Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors
    Harold J Burstein
    J Clin Oncol 25:3797-9. 2007
  92. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  93. ncbi request reprint Optimal use of aromatase inhibitors: to lead or to follow?
    Nancy U Lin
    J Clin Oncol 25:2639-41. 2007
  94. ncbi request reprint NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
    ..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting...
  95. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  96. pmc Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  97. ncbi request reprint Ovarian suppression for breast cancer: an effective treatment in search of a home
    IAN E KROP
    J Clin Oncol 23:5869-72. 2005
  98. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  99. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  100. ncbi request reprint The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Nicholas J Robert
    The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
    Semin Oncol 31:106-46. 2004
    ..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
  101. ncbi request reprint HER2 or not HER2: that is the question
    Harold J Burstein
    J Clin Oncol 23:3656-9. 2005

Research Grants2

  1. CANCER AND LEUKEMIA GROUP B
    Eric Winer; Fiscal Year: 2006
    ..The basic scientific efforts of the Dana-Farber/Harvard Cancer Center will be, where possible, brought to the correlative science program of CALGB. ..